Brief: Sanofi’s Sarclisa Subcutaneous Formulation Approved In Japan For Patients With Multiple Myeloma
19/06/2026 11:33
BRIEF-Sanofi’s Sarclisa Subcutaneous Formulation Approved In Japan For Patients With Multiple Myeloma June 19 (Reuters) - Sanofi SA SASY.PA:
PRESS RELEASE: SANOFI’S SARCLISA SUBCUTANEOUS FORMULATION APPROVED IN JAPAN FOR PATIENTS WITH MULTIPLE MYELOMA
APPROVAL BASED ON IRAKLIA PHASE 3 STUDY SHOWING NON-INFERIOR EFFICACY TO IV
CIRCLIQ ON-BODY INJECTOR FOR SARCLISA SC UNDER REVIEW IN JAPAN
SARCLISA SC VIA OBI PLUS PD SHOWS 71.1% ORR IN R/R MM
Source text: nGNXbmwK8R
Further company coverage: SASY.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))
Recent news on Sanofi SA
See all newsBrief: Sanofi’s Sarclisa Subcutaneous Formulation Approved In Japan For Patients With Multiple Myeloma
Moderna's mRNA flu vaccine backed by FDA advisers (updated)
Moderna's mRNA flu vaccine faces FDA advisory panel scrutiny
Factbox: Global drugmakers invest billions to boost US presence
Europe Research Roundup: Banca Generali, Ferrari, Prysmian